Figure 6.
Agreement between pharmacokinetic simulation predictions and subsequent clinical trial results. X-axis: Simulation predictions for mean plasma ATZ concentrations 28 days following ring placement (C29) in low-dose (290 μg/day), medium-dose (630 μg/day), and high-dose (1,080 μg/day) treatment groups. Horizontal error bars represent the 5th and 95th percentiles. Adapted from Reinecke et al. (26). Y-axis: Observed median plasma ATZ concentration as average of measurements taken 28, 56, and 84 days following first ring placement (Css) in low-dose (300 μg/day), medium-dose (600 μg/day), and high-dose (1,050 μg/day) treatment groups from a phase 2b clinical trial. Vertical error bars represent the 10th to 90th percentile. Adapted from Nave et al. (45).